TORONTO, Oct. 23 /CNW/ - Patheon (TSX:PTI), a global provider of drug
development and manufacturing services to the international pharmaceutical
industry, has opened a new Pharmaceutical Development Services (PDS) suite at
the Whitby Development Centre in Canada. The suite includes a designated area
for the small-scale development and manufacturing of solid dosage forms for
customers' early clinical study needs.
The 2500 sq ft suite is designed to give rapid response, and the facility
is GMP-compliant for manufacturing products for Phase I & II clinical studies.
By providing clinical trial materials for First Time in Human (Phase I)
studies, the suite will contribute to Patheon's Quick To Clinic(TM) offering.
The new facility will also add early-phase pharmaceutical development and
manufacturing capacity, with a manufacturing scale of 1kg to 10kg.
The suite has multiple labs with the capability for small-scale dosage
form development, as well as the manufacture of powder-in-bottle, tablets
(immediate and modified release), capsules, oral liquids, and nasal sprays.
Colin Minchom, PhD, Vice-President, Pharmaceutical Development Services,
Canada, stated, "We're very excited about the rapid response capabilities of
the new Whitby suite. This new facility will significantly strengthen
Patheon's competitiveness in the pharmaceutical and biotechnology early
Terry Novak, President, North America and Chief Marketing Officer, added,
"Patheon is committed to investing in its development services business and
with this new capacity in Whitby; we can now offer rapid early phase
development to our North American customers."
Patheon Inc. (TSX: PTI; www.patheon.com) is a leading global provider of
contract development and manufacturing services to the global pharmaceutical
industry. Patheon prides itself in providing the highest quality products and
services to more than 300 of the world's leading pharmaceutical and
biotechnology companies. Patheon's services range from preclinical development
through commercial manufacturing of a full array of dosage forms including
parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative
technologies including single-use disposables, Liquid-Filled Hard Capsules and
a variety of modified release technologies.
Patheon's comprehensive range of fully integrated Pharmaceutical
Development Services includes pre-formulation, formulation, analytical
development, clinical manufacturing, scale-up and commercialization. Patheon
can take customers direct to clinic with global clinical packaging and
distribution services and Patheon's Quick to Clinic(TM) programs can
accelerate early phase development project to clinical trials while minimizing
the consumption of valuable API. Patheon's integrated network strives to
ensure that customer products can be launched with confidence globally.
Caution Concerning Forward-Looking Statements
This news release may contain forward-looking statements which reflect
management's expectations regarding the Company's future growth of operations,
performance (both operational and financial) and business prospects and
opportunities. These statements are made in the context of the risks and
uncertainties that are outlined in the Company's public documents, which can
be accessed on our website at www.patheon.com or on SEDAR at www.sedar.com.
For further information:
For further information: Mr. Wes Wheeler, President & Chief Executive
Officer, Tel: (905) 812-2112, Email: email@example.com; Mr. Eric Evans,
Chief Financial Officer, Tel: (905) 812-6660, Email: firstname.lastname@example.org;
Ms. Jean Treadwell, Investor Relations, Tel: (905) 816-8344, Email: